IDYA · NASDAQ · Biotechnology

IDEAYA Biosciences

Develops biomarker-selected cancer drugs across small molecules and antibody-drug conjugates.

$40.11
After-hours close−0.02 (−0.05%)
At close$40.13(−3.93%)
DateEstimateReportedSurprise
Nov 2026−$1.18
Aug 2026−$1.06−$1.22−15.1%
May 2026−$1.07−$1.11−3.7%
Feb 2026−$0.95−$0.94+1.2%
Nov 2025−$0.95$1.33+240.6%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
May 2019
Sep 2018
Jun 2018
Mar 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 9, 2026−$1.18$9.9M
Aug 4, 2026−$1.06−$1.22−15.1%$8.0M$8.9M+10.4%
May 5, 2026−$1.07−$1.11−3.7%$5.0M$6.6M+30.2%
Feb 17, 2026−$0.95−$0.94+1.2%$6.3M$10.9M+72.5%
Nov 4, 2025−$0.95$1.33+240.6%$5.9M$207.8M+3,395.1%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 5, 2025
May 6, 2025
Feb 13, 2025
Nov 4, 2024
Aug 6, 2024
May 7, 2024
Feb 20, 2024
Nov 7, 2023
Aug 10, 2023
May 9, 2023
Mar 7, 2023
Nov 8, 2022
Aug 15, 2022
May 10, 2022
Mar 15, 2022
Nov 15, 2021
Aug 10, 2021
May 10, 2021
Mar 23, 2021
Nov 12, 2020
Aug 12, 2020
May 12, 2020
Mar 24, 2020
Nov 13, 2019
Aug 12, 2019
May 28, 2019
May 24, 2019
Sep 30, 2018
Jun 30, 2018
Mar 31, 2018